Janssen CarePath

Patient Support Services Guide 2018


Janssen CarePath
877-227-3728

Janssen Biotech, through Janssen CarePath, offers 1 source for patient support services, focused on access, affordability, and treatment support for patients who are prescribed a Janssen Biotech oncology medication.

The Janssen CarePath program also includes patient information about each medication offered, as well as other patient support services. Other tools are available to help patients stay on track with taking and keeping up with their medication regimens.

The complete list of Janssen Biotech’s oncology and supportive care medications is provided in the Table.

Janssen CarePath Savings Program

This program provides drug-specific reimbursement programs, patient assistance information, and resource services that facilitate patient access to Janssen oncology medications.

The Janssen CarePath Savings Program may provide patients with a rebate for their out-of-pocket prescription costs. This program is geared toward patients who have commercial or private health insurance.

Darzalex Janssen CarePath Savings Program Card

Patients who have been prescribed Darzalex (daratumumab) may be able to save on their copay, deductible, and coinsurance medication costs through the Janssen CarePath Savings Program. Patients enrolled in this program will receive a Janssen CarePath Savings Program Card that qualifies them to pay no more than $5 per infusion of Darzalex, up to a $20,000 annual benefit.

Sylvant Janssen CarePath Savings Program

Patients who have been prescribed Sylvant (siltuximab) may qualify to receive a rebate for their medication costs through the Janssen CarePath Savings Program. Patients enrolled in this program pay $50 per infusion of Sylvant, and can receive a rebate of up to $1000 per infusion.

Yondelis Janssen CarePath Savings Program Card

Patients who have been prescribed Yondelis (trabectedin) may be able to save on their copay, deductible, and coinsurance medication costs through the Janssen CarePath Savings Program. Patients enrolled in this program will receive a Janssen CarePath Savings Program Card that qualifies them to pay no more than $5 per infusion of Yondelis, with a maximum benefit of $20,000 annually.

Zytiga Janssen CarePath Savings Program Card

Patients who have been prescribed Zytiga (abiraterone acetate) may be able to save on their copay, deductible, and coinsurance costs through the Janssen CarePath Savings Program.

Patients enrolled in this program will receive a Janssen CarePath Savings Program Card that qualifies them to pay $10 monthly for Zytiga, up to a $12,000 annual benefit, 12 months after the card activation or after 12 doses, whichever comes first.

Patients who have been prescribed Darzalex, Yondelis, or Zytiga who are enrolled in their drug-specific Janssen CarePath Savings Program will get a Janssen CarePath Savings Program Card that qualifies them to receive the program’s savings.

Johnson & Johnson Patient Assistance Foundation

Johnson & Johnson Patient Assistance Foundation is an independent, nonprofit organization that helps patients without adequate financial resources and with no prescription coverage obtain their medications. The program is drug-specific, and qualifying patients may be eligible to receive free Janssen medications for up to 12 months.

Information about the Johnson & Johnson Patient Assistance Foundation, including medications available through the foundation’s patient assistance program, is available at JJPAF.org.

Eligibility

Janssen CarePath Savings Program

Patients may qualify for enrollment in the Janssen CarePath Savings Program if they currently have private or commercial health insurance that will cover a portion of the cost of medication, including Darzalex, Sylvant, or Yondelis. Patients participating in federally or state-funded programs are not eligible for the savings program. Those patients are directed to programs that can help them to afford their medications. Drug-specific eligibility criteria are available online.

Johnson & Johnson Patient Assistance Foundation

To qualify for enrollment in the Johnson & Johnson Patient Assistance Foundation, patients must:

  • Reside in the United States or its territories
  • Receive outpatient treatment from a licensed US provider
  • Lack prescription drug coverage
  • Meet drug-specific income eligibility requirements, available at www.jjpaf.org/eligibility.

Janssen CarePath Savings Program Cards

Patients who are prescribed Janssen Biotech medications may qualify for a drug-specific Janssen CarePath Savings Program Card if they meet the following criteria:

  • They have been prescribed Darzalex, Yondelis, or Zytiga
  • They have eligible private insurance
  • They are not enrolled in a federally or a state-subsidized healthcare plan or program.

These eligibility criteria also apply to patients who have been prescribed Sylvant if they enroll in the Sylvant Janssen CarePath Savings Program to receive a rebate for the medication cost.

Application & Enrollment

Janssen CarePath Savings Program

The enrollment process for this program varies by medication. To learn more about the application process for a specific drug, visit JanssenCarePath.com and select the prescribed medication from the drop-down menu.

Johnson & Johnson Patient Assistance Foundation

To enroll in the Johnson & Johnson Patient Assistance Foundation, patients and physicians must complete the Patient Assistance Program Application form.

Applications, and any required documentation, may be faxed to 888-526-5168, or mailed to the address listed on the form. The patient’s medical information, including the diagnosis (and a diagnosis code) and medication-specific information (with the dosage), must be completed. For Procrit (epoetin alfa), the hemoglobin level based on the most recent laboratory results must be included.

Reimbursement

Information about reimbursement support programs for eligible patients is accessible through the CarePath portal (JanssenCarePath.com). Reimbursement programs are drug-specific. The reimbursement programs pertaining to Janssen’s oncology and oncology supportive care drugs are drug-specific.

Darzalex (daratumumab): Information about Darzalex reimbursement programs can be found online or by phone at 844-553-2792.

Doxil (doxorubicin hydrochloride liposome injection): CarePath offers Doxil-specific reimbursement support, resources, and tools for patients and providers. More information is available online or by calling 800-609-1083.

Procrit (epoetin alfa): Procrit-specific reimbursement support, resources, and tools for patients and providers are available online or over the phone by dialing 800-553-3851.

Sylvant (siltuximab): For further information on patient support for Sylvant, visit this website or call 855-299-8844.

Yondelis (trabectedin): For patients who are prescribed infusions of Yondelis, visit this website for more information, or call 844-966-3354.

Zytiga (abiraterone acetate): Patients who have been prescribed Zytiga may be able to save on copays, deductibles, and coinsurance. Enrollment forms are available online.

Table Janssen Biotech Oncology/Supportive Care Drugs

Drugs
Indications
Patient support programs

Drug
Darzalex (daratumumab)
Indication
Multiple myeloma, in combination with lenalidomide and dexamethasone, or with bortezomib and dexamethasone, after ≥1 previous therapies; multiple myeloma, in combination with pomalidomide and dexamethasone after ≥2 previous therapies, including lenalidomide and a proteasome inhibitor; multiple myeloma, as monotherapy, after ≥3 previous lines of therapy

Drug
Doxil (doxorubicin hydrochloride liposome injection)
Indication
Ovarian cancer; AIDS-related Kaposi’s sarcoma; multiple myeloma, in combination with bortezomib

Drug
Procrit (epoetin alfa)
Indication
Chemotherapy-induced anemia

Drug
Sylvant (siltuximab)
Indication
Multicentric Castleman’s disease

Drug
Yondelis (trabectedin)
Indication
Unresectable or metastatic liposarcoma or leiomyosarcoma

Drug
Zytiga (abiraterone acetate)
Indication
Metastatic castration-resistant prostate cancer